Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Goldfinch shuts down, Karuna snaps up drug candidates

by Gina Vitale
February 10, 2023 | A version of this story appeared in Volume 101, Issue 6

 

Karuna Therapeutics is snapping up assets from Goldfinch Bio, a developer of kidney disease medicine that is closing its doors. Karuna, which develops medicines for psychiatric and neurological conditions, will pay the assignment estate of Goldfinch $15 million up front for global development, manufacturing, and commercialization rights to several of Goldfinch’s drug candidates. The assignment estate may also get up to $520 million in milestones for each licensed candidate. Among the potential drugs Karuna gets the rights to is the lead clinical-stage candidate GFB-887, which it will evaluate for treating mood and anxiety disorders.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.